Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor
Multiple Sclerosis (MS) - Relapsing-remitting

About this trial
This is an interventional treatment trial for Multiple Sclerosis (MS) - Relapsing-remitting focused on measuring relapsing-remitting MS, nonresponsive to standard of care MS, sirolimus
Eligibility Criteria
Inclusion Criteria: Relapsing-remitting MS Evidence of demyelination on magnetic resonance imaging (MRI) scan Expanded Disability Status Scale (EDSS) score between 0 and 6 Nonresponsive to beta-interferon or Glatiramer acetate therapy Discontinuation of beta-interferon or Glatiramer acetate therapy within 1 month prior to study entry Willing to use acceptable methods of contraception Exclusion Criteria: Primary progressive MS Prior treatment with immunosuppressants Steroid therapy within 1 month prior to study entry Evidence of active infection or cancer Heart or hematologic dysfunction High levels of lipids in the blood Use of lipid-lowering agents History of cirrhosis or liver disease requiring treatment History of hepatitis B or C Active cytomegalovirus infection Kidney disease requiring treatment Active lung disease Diabetes Hyperthyroidism HIV infection Tuberculosis History of alcohol or drug abuse within 6 months prior to study entry Claustrophobia or inability to undergo MRI Pregnancy or breast-feeding
Sites / Locations
- Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School
Arms of the Study
Arm 1
Experimental
sirolimus